Iluvien (Fluocinolone Acetonide)

Fluocinolone acetonide activates glucocorticoid receptors in ocular tissues, suppressing inflammatory cytokines and reducing vascular leakage. The sustained‑release implant provides a continuous, low‑level exposure within the vitreous cavity, maintaining anti‑inflammatory activity while limiting systemic exposure.

Iluvien is supplied as a single‑use 0.19 mg intravitreal implant. The exact dosing schedule, including whether a repeat implantation is needed, is determined by the prescribing ophthalmologist based on the patient’s clinical response and disease progression.

The safety of Iluvien in pregnancy and lactation has not been established. Because the implant delivers a corticosteroid directly to the eye, clinicians should weigh potential risks and benefits and consider alternative therapies when treating pregnant or nursing patients.

To request Iluvien, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Iluvien provides a sustained‑release delivery of fluocinolone acetonide for up to 36 months, reducing the need for frequent injections. Compared with short‑acting intravitreal steroids such as triamcinolone or dexamethasone implants, Iluvien offers longer durability but may carry a higher cumulative risk of intraocular pressure rise and cataract formation.

Store Iluvien at ambient temperature, below 25 °C. Keep the implant in its original sealed container, protect it from moisture and direct sunlight, and avoid exposing it to extreme temperatures or mechanical shock.

Iluvien is implanted into the vitreous cavity of the eye by a qualified ophthalmic surgeon using a specialized applicator. The procedure is performed under sterile conditions, typically in an operating room or a designated procedure suite, and does not require systemic administration.

The most serious risks include sustained elevation of intraocular pressure that may lead to glaucoma, development or progression of cataracts requiring surgery, and rare but severe complications such as endophthalmitis, retinal detachment, or vitreous hemorrhage. Patients should be monitored regularly for these events.

Iluvien is contraindicated in patients with active ocular infection, uncontrolled glaucoma, or a known hypersensitivity to fluocinolone acetonide or any component of the implant. It should also be avoided in individuals who have received another intravitreal corticosteroid implant within the same eye.